Continuous Bio-Manufacturing Skid Market Report 2026

The continuous bio-manufacturing skid market size has grown rapidly in recent years. It will grow from $1.99 billion in 2025 to $2.26 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to growth in biologics production volumes, early transition from batch to continuous processing, rising adoption of modular manufacturing concepts, expansion of vaccine and enzyme production facilities, increasing demand for flexible manufacturing setups.

The continuous bio-manufacturing skid market size is expected to see rapid growth in the next few years. It will grow to $3.73 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing deployment of fully continuous biologics production, rising investments in advanced bioprocess automation, growing demand for rapid scale-up capabilities, expansion of cell and gene therapy manufacturing, increasing focus on cost-efficient biologics production. Major trends in the forecast period include increasing adoption of continuous and integrated bioprocessing skids, rising demand for modular and plug-and-play manufacturing systems, growing use of real-time process monitoring and control, expansion of single-use continuous biomanufacturing platforms, enhanced focus on process efficiency and throughput.

The rising demand for biopharmaceuticals is expected to drive the growth of the continuous bio-manufacturing skid market in the coming years. Biopharmaceuticals are medicinal products developed using biological sources, such as proteins, nucleic acids, or living cells, to treat, prevent, or diagnose diseases. The growing demand for biopharmaceuticals is mainly fueled by the increasing prevalence of chronic and genetic disorders, which require advanced biologic therapies for effective treatment and management. Continuous bio-manufacturing skid improves biopharmaceutical production by providing streamlined, automated, and scalable processes that enhance efficiency, consistency, and speed in developing complex therapies. For example, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, the U.S. had 40 FDA-approved biosimilar products by 2023, with 25 available on the market. In comparison, as of January 2022, there were 33 FDA-approved biosimilars, of which 21 were commercially available. Thus, the rising demand for biopharmaceuticals is fueling the growth of the continuous bio-manufacturing skid market.

Major companies in the continuous bio-manufacturing skid market are concentrating on developing innovative solutions, such as advanced biologics manufacturing platforms, to improve efficiency, scalability, and product quality. Advanced biologics manufacturing platforms are sophisticated systems that enable fully integrated, continuous production of biologics with real-time monitoring, enhanced efficiency, and consistent product quality. For example, in October 2024, Enzene Biosciences Ltd., an India-based contract development and manufacturing organization, introduced EnzeneX 2 at CPHI Milan 2024, the next generation of its fully connected continuous manufacturing (FCCM) technology for biologics. This patented platform allows seamless, uninterrupted processing from perfusion to final drug substance. By utilizing high-titer clones and optimized cell media, it boosts productivity, increases target protein concentrations, and reduces batch-to-batch variability. The system also integrates process analytical technology (PAT) for real-time monitoring and control, ensuring consistent quality and operational efficiency, while providing up to a 50% reduction in production costs per gram. These platforms offer scalable, cost-effective biologics manufacturing that can be adapted to various modalities and media formulations.

In June 2023, Donaldson Company Inc., a US-based filtration technology firm, acquired Univercells Technologies for $159 million (€136 million). Through this acquisition, Donaldson intends to broaden its life sciences portfolio by incorporating Univercells Technologies’ innovative single-use bioreactors and automated upstream platforms to provide comprehensive and advanced biomanufacturing solutions for cell and gene therapies, vaccines, and other biologics. Univercells Technologies S.A. is a Belgium-based company offering advanced biomanufacturing solutions that utilize intensified and integrated continuous processing principles.

Major companies operating in the continuous bio-manufacturing skid market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Garrett Industrial Systems Ltd., Sartorius AG, Getinge AB, ZETA GmbH, Pall Corporation, Repligen Corporation, ABEC Inc., Enzene Biosciences Limited, Pierre Guerin Technologies, Bioengineering AG, KeyPlants GmbH, G&G Technologies Pvt. Ltd., Scigenics Pvt. Ltd, Exentec B.V., PAK BioSolutions Inc., Stobbe Pharma GmbH, CPi Biotech Inc.

North America was the largest region in the continuous bio-manufacturing skid market in 2025. The regions covered in the continuous bio-manufacturing skid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the continuous bio-manufacturing skid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the continuous bio-manufacturing skid market by increasing costs of imported stainless steel components, automation systems, sensors, pumps, and filtration modules used in upstream, downstream, and integrated skids. Biopharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported skid assemblies, while Asia-Pacific faces pricing pressure on export-oriented skid fabrication. These tariffs are increasing upfront system costs and slowing facility expansion decisions. However, they are also driving regional skid manufacturing, localized system integration, and innovation in standardized and cost-optimized continuous biomanufacturing solutions.

The continuous bio-manufacturing skid market research report is one of a series of new reports that provides continuous bio-manufacturing skid market statistics, including continuous bio-manufacturing skid industry global market size, regional shares, competitors with a continuous bio-manufacturing skid market share, detailed continuous bio-manufacturing skid market segments, market trends and opportunities, and any further data you may need to thrive in the continuous bio-manufacturing skid industry. This continuous bio-manufacturing skid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A continuous bio-manufacturing skid is a compact, pre-assembled system engineered to perform continuous production of biologics, incorporating unit operations such as fermentation, purification, and formulation into a unified workflow. It facilitates automated, scalable, and efficient biomanufacturing while reducing manual intervention and process variability.

The main product types of continuous bio-manufacturing skids include single-use skids, multi-use skids, and modular skids. Single-use skids are fully integrated, disposable systems designed for the continuous production of biologics, where all product-contacting components are single-use, reducing the risk of cross-contamination and the need for cleaning while supporting uninterrupted upstream or downstream processing. These skids accommodate various processes such as upstream, downstream, and integrated operations. They are applied in a wide range of areas, including biopharmaceutical production, vaccine manufacturing, enzyme production, cell and gene therapy, and more, and cater to diverse end users, including pharmaceutical companies, biotechnology firms, contract manufacturing organizations, research institutes, and other users.

The continuous bio-manufacturing skid market consists of sales of bioprocessing equipment, monitoring and control systems, sensors, pumps, tubing assemblies, valves, mixing systems, and control panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.